A novel all-in-one injectable composed of tenofovir alafenamide–dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks
Authors:
- 4 May 2026
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (10) , 1420-1425
Abstract
Objective: To investigate the novel 3-in-one long-acting injectable product composed of tenofovir alafenamide (TAF), dolutegravir (D), and lamivudine (L), as a complete TAF-DL product for pediatric HIV treatment. Design: TAF-DL sterile injectable product is assembled with 3-HIV drugs and amphipathic lipids. It is built on the drug-combination-nanoparticle (DcNP) platform via a well-defined manufacturing process. Plasma concentrations for all 3 drugs were determined in 12 juvenile nonhuman primates (NHP, M. nemestrina ) following subcutaneous administration. Safety parameters monitored. Results: Following a single dose of TAF-DL-in-DcNP , all drugs exhibited long-acting cell-and plasma profiles in juvenile NHP for 8 weeks. Time-to-peak occurred within 24 hr, for all drugs. Compared to free-soluble counterpart, DcNP formulation enhanced TAF, D and L half-life by 23, 5.8, 8.3-fold; and AUC by 41, 18, 3.1-fold. Cell targeting enabled by DcNP is noted as higher intracellular PBMC versus plasma concentration of TAF, tenofovir (T), D, L in NHP dosed with TAF-DL-in-DcNP product. Safety assessment in 12 juvenile-NHPs noted no injection site reactions, or change in weight, complete blood count, and serum chemistries over 8 weeks. Conclusions: Current 3-HIV oral drugs, TAF-DL is successfully transformed into a novel, single long-acting injectable product that may support once-every-two-month dosing. TAF-DL-in-Dc NP enhanced HIV host-lymphocyte drug exposure. With less than 24 hr to reach C max , the all-in-one product may overcome the need for an oral-lead-in typically required to initiate LA injectables. TAF-DL-in-DcNP product appears to be safe in juvenile NHPs.Keywords
This publication has 26 references indexed in Scilit:
- Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP)Journal of Pharmaceutical Sciences, 2025
- Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kgJournal of the International AIDS Society, 2025
- Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP ProductsJournal of Pharmaceutical Sciences, 2024
- Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic reviewJournal of the International AIDS Society, 2023
- Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination NanoparticlesJournal of Pharmaceutical Sciences, 2022
- Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug MixtureJournal of Pharmaceutical Sciences, 2021
- Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101Journal of Pharmaceutical Sciences, 2020
- Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman PrimatesJournal of Pharmaceutical Sciences, 2018
- Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous InjectionJournal of Pharmaceutical Sciences, 2018
- Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in MonkeysMolecular Pharmaceutics, 2009